Cargando…
IER3 (IEX‐1) dysregulation serves as a potential prognostic factor in acute myeloid leukemia patients
INTRODUCTION: Immediate early response 3 (IER3) has association with hematological malignancies’ risk and prognosis, such as myelodysplastic syndrome, while its relation to acute myeloid leukemia (AML) is not clear. This study aimed to explore the correlation of IER3 with AML risk, clinical characte...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298238/ https://www.ncbi.nlm.nih.gov/pubmed/34729939 http://dx.doi.org/10.1111/ijlh.13749 |
_version_ | 1784750658487844864 |
---|---|
author | Ke, Shandong Zhang, Xin Xiang, Xiuzhi Lu, Yalan An, Hongyu |
author_facet | Ke, Shandong Zhang, Xin Xiang, Xiuzhi Lu, Yalan An, Hongyu |
author_sort | Ke, Shandong |
collection | PubMed |
description | INTRODUCTION: Immediate early response 3 (IER3) has association with hematological malignancies’ risk and prognosis, such as myelodysplastic syndrome, while its relation to acute myeloid leukemia (AML) is not clear. This study aimed to explore the correlation of IER3 with AML risk, clinical characteristics, complete remission (CR), event‐free survival (EFS), and overall survival (OS). METHODS: A total of 93 de novo AML patients were included in this study. In addition, 30 patients with non‐hyperplasia hematologic malignancies requiring bone marrow testing (as disease controls) and 30 health donors (as health controls) were also recruited. Bone morrow samples of AML patients (before treatment), disease controls (before treatment), and health controls (at donation) were collected. IER3 in bone marrow mononuclear cells was detected by reverse transcription‐quantitative polymerase chain reaction. RESULTS: IER3 was increased in AML patients compared with disease controls and health donors (both P < .001), and receiver operating characteristic (ROC) curve showed that IER3 had certain capability of distinguishing AML patients from disease controls (area under curve (AUC): 0.735, 95% confidence interval (CI): 0.650‐0.820), and health donors (AUC: 0.789, 95% CI: 0.712‐0.866). Meanwhile, IER3 was correlated with FLT3‐ITD mutation (P = .030) and poor NCCN risk stratification (P = .031) in AML patients. Moreover, IER3 had negative association with CR in AML patients (P = .022), and showed certain potential in discriminating CR patients from non‐CR patients (AUC: 0.655, 95% CI: 0.533‐0.777). Besides, IER3 was negatively associated with EFS (P = .033), but not OS (P = .083) in AML patients. CONCLUSION: IER3 dysregulation serves as a potential prognostic factor in AML patients. |
format | Online Article Text |
id | pubmed-9298238 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92982382022-07-21 IER3 (IEX‐1) dysregulation serves as a potential prognostic factor in acute myeloid leukemia patients Ke, Shandong Zhang, Xin Xiang, Xiuzhi Lu, Yalan An, Hongyu Int J Lab Hematol Original Articles INTRODUCTION: Immediate early response 3 (IER3) has association with hematological malignancies’ risk and prognosis, such as myelodysplastic syndrome, while its relation to acute myeloid leukemia (AML) is not clear. This study aimed to explore the correlation of IER3 with AML risk, clinical characteristics, complete remission (CR), event‐free survival (EFS), and overall survival (OS). METHODS: A total of 93 de novo AML patients were included in this study. In addition, 30 patients with non‐hyperplasia hematologic malignancies requiring bone marrow testing (as disease controls) and 30 health donors (as health controls) were also recruited. Bone morrow samples of AML patients (before treatment), disease controls (before treatment), and health controls (at donation) were collected. IER3 in bone marrow mononuclear cells was detected by reverse transcription‐quantitative polymerase chain reaction. RESULTS: IER3 was increased in AML patients compared with disease controls and health donors (both P < .001), and receiver operating characteristic (ROC) curve showed that IER3 had certain capability of distinguishing AML patients from disease controls (area under curve (AUC): 0.735, 95% confidence interval (CI): 0.650‐0.820), and health donors (AUC: 0.789, 95% CI: 0.712‐0.866). Meanwhile, IER3 was correlated with FLT3‐ITD mutation (P = .030) and poor NCCN risk stratification (P = .031) in AML patients. Moreover, IER3 had negative association with CR in AML patients (P = .022), and showed certain potential in discriminating CR patients from non‐CR patients (AUC: 0.655, 95% CI: 0.533‐0.777). Besides, IER3 was negatively associated with EFS (P = .033), but not OS (P = .083) in AML patients. CONCLUSION: IER3 dysregulation serves as a potential prognostic factor in AML patients. John Wiley and Sons Inc. 2021-11-02 2022-04 /pmc/articles/PMC9298238/ /pubmed/34729939 http://dx.doi.org/10.1111/ijlh.13749 Text en © 2021 The Authors. International Journal of Laboratory Hematology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Ke, Shandong Zhang, Xin Xiang, Xiuzhi Lu, Yalan An, Hongyu IER3 (IEX‐1) dysregulation serves as a potential prognostic factor in acute myeloid leukemia patients |
title | IER3 (IEX‐1) dysregulation serves as a potential prognostic factor in acute myeloid leukemia patients |
title_full | IER3 (IEX‐1) dysregulation serves as a potential prognostic factor in acute myeloid leukemia patients |
title_fullStr | IER3 (IEX‐1) dysregulation serves as a potential prognostic factor in acute myeloid leukemia patients |
title_full_unstemmed | IER3 (IEX‐1) dysregulation serves as a potential prognostic factor in acute myeloid leukemia patients |
title_short | IER3 (IEX‐1) dysregulation serves as a potential prognostic factor in acute myeloid leukemia patients |
title_sort | ier3 (iex‐1) dysregulation serves as a potential prognostic factor in acute myeloid leukemia patients |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298238/ https://www.ncbi.nlm.nih.gov/pubmed/34729939 http://dx.doi.org/10.1111/ijlh.13749 |
work_keys_str_mv | AT keshandong ier3iex1dysregulationservesasapotentialprognosticfactorinacutemyeloidleukemiapatients AT zhangxin ier3iex1dysregulationservesasapotentialprognosticfactorinacutemyeloidleukemiapatients AT xiangxiuzhi ier3iex1dysregulationservesasapotentialprognosticfactorinacutemyeloidleukemiapatients AT luyalan ier3iex1dysregulationservesasapotentialprognosticfactorinacutemyeloidleukemiapatients AT anhongyu ier3iex1dysregulationservesasapotentialprognosticfactorinacutemyeloidleukemiapatients |